Shopping Cart
Remove All
Your shopping cart is currently empty
Burosumab(KRN23) is a human monoclonal antibody targeting fibroblast growth factor 23 (FGF23) for the treatment of cutaneous-skeletal hypophosphatemic syndrome (CSHS) and tumor-induced osteochondrosis.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $213 | - | In Stock | |
| 5 mg | $497 | - | In Stock | |
| 10 mg | $797 | - | In Stock |
| Description | Burosumab(KRN23) is a human monoclonal antibody targeting fibroblast growth factor 23 (FGF23) for the treatment of cutaneous-skeletal hypophosphatemic syndrome (CSHS) and tumor-induced osteochondrosis. |
| Synonyms | KRN23 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Molecular Weight | 144.08 kDa |
| Cas No. | 1610833-03-8 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.